SEC Comment Letter 0000000000-24-005391 to MoonLake Immunotherapeutics (MLTX) (CIK 0001821586) (MLTX)
MoonLake Immunotherapeutics (MLTX) (CIK 0001821586)
Date: May 13, 2024 · CIK: 0001821586 · Accession: 0000000000-24-005391
AI Filing Summary & Sentiment
File numbers found in text: 001-39630
Letter
United States securities and exchange commission logo May 13, 2024 Matthias Bodenstedt Chief Financial Officer MoonLake Immunotherapeutics Dorfstrasse 29, 6300 Zug Switzerland Re:MoonLake Immunotherapeutics Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-39630 Dear Matthias Bodenstedt: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 13, 2024
Matthias Bodenstedt
Chief Financial Officer
MoonLake Immunotherapeutics
Dorfstrasse 29, 6300
Zug Switzerland
Re:MoonLake Immunotherapeutics
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-39630
Dear Matthias Bodenstedt:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences